Cancer continues to be one of the most challenging diseases to treat worldwide. The three main methods used to treat cancer are surgical excision, chemotherapy, and radiation therapy. Immunotherapy has had a major impact on the prognosis for treating cancers like renal cell carcinoma, non-small cell lung cancer, and melanoma. A variety of cancer treatments are included in immunotherapy, such as immune checkpoint inhibitors (ICIs), chimeric antigen receptor (CAR) T-cell therapy, monoclonal antibodies, vaccines, and immune system modulators. These treatments work to strengthen the immune system's capacity to identify and eliminate cancer cells by focusing on various mechanisms. Although cancer cells can be effectively monitored and identified by the immune system at first, the immune-altering effects of the disease may cause the cells to enter an immune escape state. Cancer cells develop complex defense mechanisms to prevent the immune system from recognizing and eliminating them. Immune evasion in cancer is one of the main mechanisms leading to disease progression and metastasis. In recent years, our understanding of immune responses in tumors and tumor microenvironments (TIME) has expanded. One of the greatest current challenges in cancer treatment is to understand the complex and dynamic interaction between tumor and stromal cells, as well as the regulation of inflammation and the inhibition or progression of tumors.
In this research topic, we aim to provide information on most recent advancements in the fundamental mechanisms of cancer immune evasion as well as the efficacy of therapeutic targets and agents in combating immune evasion.
We welcome submissions of Original Research Articles, Systematic Review, Meta-analysis, Reviews, and Mini-reviews, including but not limited to the following subtopics:
• Development of novel preclinical cancer models (in vitro and in vivo)
• Discovery of novel therapeutics to overcome immune evasion in cancer.
• Identification of novel biomarkers (genes, miRNA, lncRNA, circulating tumor cells (CTCs), exosomes, and proteins) involve in immune evasion of cancer
• Molecular cross-talk studies on tumor metabolic pathways and tumor microenvironment (TIME)
• Utilization of advanced omics techniques to study the contributing factors of immune evasion in cancer (including high-throughput sequencing like single cell RNA-Seq, spatial transcriptomics, and AI-driven models).
• Therapeutic implications of cancer immunotherapy (clinical studies)
Please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases (except AI-driven models) which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Cancer continues to be one of the most challenging diseases to treat worldwide. The three main methods used to treat cancer are surgical excision, chemotherapy, and radiation therapy. Immunotherapy has had a major impact on the prognosis for treating cancers like renal cell carcinoma, non-small cell lung cancer, and melanoma. A variety of cancer treatments are included in immunotherapy, such as immune checkpoint inhibitors (ICIs), chimeric antigen receptor (CAR) T-cell therapy, monoclonal antibodies, vaccines, and immune system modulators. These treatments work to strengthen the immune system's capacity to identify and eliminate cancer cells by focusing on various mechanisms. Although cancer cells can be effectively monitored and identified by the immune system at first, the immune-altering effects of the disease may cause the cells to enter an immune escape state. Cancer cells develop complex defense mechanisms to prevent the immune system from recognizing and eliminating them. Immune evasion in cancer is one of the main mechanisms leading to disease progression and metastasis. In recent years, our understanding of immune responses in tumors and tumor microenvironments (TIME) has expanded. One of the greatest current challenges in cancer treatment is to understand the complex and dynamic interaction between tumor and stromal cells, as well as the regulation of inflammation and the inhibition or progression of tumors.
In this research topic, we aim to provide information on most recent advancements in the fundamental mechanisms of cancer immune evasion as well as the efficacy of therapeutic targets and agents in combating immune evasion.
We welcome submissions of Original Research Articles, Systematic Review, Meta-analysis, Reviews, and Mini-reviews, including but not limited to the following subtopics:
• Development of novel preclinical cancer models (in vitro and in vivo)
• Discovery of novel therapeutics to overcome immune evasion in cancer.
• Identification of novel biomarkers (genes, miRNA, lncRNA, circulating tumor cells (CTCs), exosomes, and proteins) involve in immune evasion of cancer
• Molecular cross-talk studies on tumor metabolic pathways and tumor microenvironment (TIME)
• Utilization of advanced omics techniques to study the contributing factors of immune evasion in cancer (including high-throughput sequencing like single cell RNA-Seq, spatial transcriptomics, and AI-driven models).
• Therapeutic implications of cancer immunotherapy (clinical studies)
Please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases (except AI-driven models) which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.